Richard D. Francis
Known title: President and CEOCIK: 0001673277
Associated companies
this person other insiders at TEVA
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Morgan Stanley raises Mettler-Toledo price target to $1,575. Morgan Stanley maintained an Equal-Weight rating on Mettler-Toledo while raising its price target to $1,575. This action aligns with the current average analyst target of $1,529.46, which sits below the stock's 52-week high of $1,619.58. The company is also scheduled to host an investor meeting in the near term.
Transaction History
| TEVA | ▲ Buy | Option Exercise | 13,043 | — | 6/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,153 | $211K | 6/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 42,452 | — | 3/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 20,025 | $634K | 3/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 50,223 | — | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 23,393 | $759K | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 67,231 | — | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 30,903 | $1.0M | 3/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 891,315 | — | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 412,032 | $13.3M | 3/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 161,656 | — | 2/15/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 161,656 | $5.5M | 2/15/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 620,110 | — | 2/15/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 286,122 | $9.8M | 2/15/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 8,259 | $131K | 3/5/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,450 | $100K | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 50,223 | — | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 15,514 | $244K | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 24,892 | $403K | 3/3/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 67,231 | — | 3/3/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 75,506 | $1.3M | 2/18/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 161,655 | — | 2/15/2025 | View on chart |
| MTD | ▲ Buy | Grant | 71 | $0 | 11/12/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 31,061 | $414K | 3/4/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 67,231 | — | 3/3/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 161,655 | — | 2/15/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 74,530 | $980K | 2/15/2024 | View on chart |
| MTD | ▲ Buy | Grant | 49 | $0 | 11/9/2023 | View on chart |
| MTD | ▲ Buy | Grant | 41 | $0 | 11/3/2022 | View on chart |
| MTD | ▲ Buy | Grant | 30 | $0 | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.